康哲药业(00867)今日盘中大幅上涨5.09%，引起了市场的广泛关注。
消息面上，多家大行发布研报，看好公司未来发展并上调目标价。其中，中金公司发布报告称，考虑新品放量，上调康哲药业2026/2027年经调净利润预测6%及9%，并同步上调目标价6%至17.50港元，维持“跑赢行业”评级，报告指出其创新药和独家药品已成为核心增长引擎，战略转型成效彰显。
与此同时，花旗银行也发布报告，维持康哲药业“买入”评级，并将目标价由16.6港元上调至17.5港元，以反映管理层对创新药快速增长的指引。公司2025年业绩显示营收重回增长，创新药及独家药收入同比大幅增长44.1%，尽管因一次性税务支出导致账面利润下滑，但调整后净利润保持增长，增长动能全面焕新。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.